SCHEMBL4209368

SCHEMBL4209368

CCCCOc1cc(C=C(C)C(=O)O)ccc1-c1cccc(CNCC(=O)c2cccc(OC)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
DHODH Q02127 1/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
EPHX2 P34913 4/20 0.37
FAAH O00519 1/20 0.37
PTPN11 Q06124 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209357 1.00 LMNA (0.41) LMNAMAPK1HTTTDP1L3MBTL1
SCHEMBL4211967 0.94 MEN1 (0.37) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL4211976 0.94 MEN1 (0.37) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL4209272 0.92 KDM4E (0.41) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL4219792 0.92 KDM4E (0.41) L3MBTL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL4213898 0.83 HSD17B2 (0.46) LMNAMAPK1HTTTDP1L3MBTL1
SCHEMBL4219912 0.83 ALOX5 (0.39) MEN1KMT2AALDH1A1KDM4EEPHX2
SCHEMBL4361050 0.82 KDM4E (0.38) ALDH1A1KDM4EPTPN11FFAR1
SCHEMBL4361055 0.82 KDM4E (0.38) ALDH1A1KDM4EPTPN11FFAR1
SCHEMBL4211240 0.82 HTR7 (0.43) ALDH1A1KDM4EPTPN11FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA LMNA 3394/4885MAPK1 2286/4885HTT 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.